CD BioSciences Announces Cytoskeleton-Targeted Tumor Marker Development Service for Cancer Diagnosis
CD BioSciences, a prominent biotech company, has recently unveiled its latest and innovative service on cytoskeleton-based tumor marker development. This groundbreaking service can be utilized for preclinical tests to determine the tumor type and predict disease progression.
The cytoskeleton refers to the network of protein filaments within cells that plays a crucial role in...